Preferential consumption of coagulation factors I, V, and VIII in rat endotoxemia.
To ascertain the time course of prolonged coagulation time and the coagulation factors that were consumed preferentially after injection of Escherichia coli endotoxin (ETX, 3 mg/kg, intravenously) in rats, the activated partial thromboplastin time (aPTT) and prothrombin time (PT) were measured. Using aPTT and PT, the residual levels of the major coagulation factors were quantified by partial replacement of ETX-injected rat plasma with individual factor-deficient human plasma. The residual levels of prekallikrein and high molecular weight (HMW) kininogen were also measured. After ETX injection, aPTT and PT showed gradual increasing prolongation, which was marked at 3-5 h after the injection. The residual level of fibrinogen was markedly reduced between 1 and 3 h after ETX injection and dropped to the determination limit 7 h after the injection. Ratios of the consumed coagulation factors, prekallikrein, and HMW kininogen in rat plasma collected 7 h after intravenous injection of ETX were obtained as follows: prekallikrein (18.0 +/- 4.8%), HMW kininogen (36.2 +/- 1.9 %), factor XII (54.0 +/- 0.7%), factor VIII (86.1 +/- 1.8%), factor VII (35.6 +/- 7.7%), factor V (90.6 +/- 0.8%), and factor I (fibrinogen) (>89.6 +/- 0.0%). Thus, coagulation factor I (fibrinogen) and factors V and VIII (cofactors) were consumed preferentially. The extrinsic coagulation pathway was dominantly activated, whereas the intrinsic coagulation pathway, including plasma kallikrein-kinin system, played less important role in the ETX-induced consumption coagulopathy in rat.
Yamaguchi
K
K
Department of Trauma and Critical Care, Yokosuka Kyosai Hospital, Kanagawa, Japan.
Majima
M
M
Katori
M
M
Kakita
A
A
Sugimoto
K
K
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D019446:Endotoxemia / Q000097:blood*; D004731:Endotoxins / Q000008:administration & dosage / Q000633:toxicity*; D005165:Factor V / Q000378:metabolism*; D005169:Factor VIII / Q000378:metabolism*; D005174:Factor XII / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D019679:Kininogen, High-Molecular-Weight / Q000097:blood; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D010314:Partial Thromboplastin Time; D011288:Prekallikrein / Q000378:metabolism; D011517:Prothrombin Time; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D004731:Endotoxins; D019679:Kininogen, High-Molecular-Weight; D008070:Lipopolysaccharides; C044101:endotoxin, Escherichia coli; D005165:Factor V; D005169:Factor VIII; D005174:Factor XII; D005340:Fibrinogen; D011288:Prekallikrein